Immunoselection of functional CMRF-56+ blood dendritic cells from multiple myeloma patients for immunotherapy

Journal of Immunotherapy

Volumn 28, Issue 4, 2005, Pages 322-331

  Radford, Kristen J ^a   Turtle, Cameron J ^a   Kassianos, Andrew J ^a   Vuckovic, Slavica ^a   Gardiner, Damien ^a   Khalil, Dahlia ^a   Taylor, Kerry ^b   Wright, Sue ^b   Gill, Devinder ^c   Hart, Derek N J ^a  

^a MATER MEDICAL RESEARCH INSTITUTE   (Australia)

^b MATER ADULT HOSPITAL   (Australia)

^c PRINCESS ALEXANDRA HOSPITAL   (Australia)

Author keywords

Dendritic cell; Immunoselection; Multiple myeloma; Tumor immunotherapy

Indexed keywords

ANTIBODY; CD123 ANTIGEN; CD16 ANTIGEN; CMRF 56 ANTIBODY; GLYCOPROTEIN P 15095; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANTIGEN PURIFICATION; ARTICLE; CANCER IMMUNOTHERAPY; CANCER RELAPSE; CELL ACTIVATION; CELL ISOLATION; CELL SELECTION; CELL SURVIVAL; DENDRITIC CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; MULTIPLE MYELOMA; NORMAL HUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS;

EID: 21844470240     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cji.0000163592.66910.e4     Document Type: Article

References (52)

1. Hart DN, Hill GR. Dendritic cell immunotherapy for cancer: application to low-grade lymphoma and multiple myeloma. Immunol Cell Biol. 1999; 77:451-459.
2. Brossait P, Schneider A, Dill P, et al. The epithelial tumor antigen MUC1 is expressed in hematological malignancies and is recognized by MUC1-specific cytotoxic T-lymphocytes. Cancer Res. 2001;61:6846-6850.
3. Vonderheide RH, Schultze JL, Anderson KS, et al. Equivalent induction of telomerase-specific cytotoxic T lymphocytes from tumor-bearing patients and healthy individuals. Cancer Res. 2001;61:8366-8370.
4. Chiriva-Internati M, Wang Z, Salati E, et al. Sperm protein 17 (Sp17) is a suitable target for immunotherapy of multiple myeloma. Blood. 2002; 100:961-965.
5. Cull G, Durrant L, Stainer C, et al. Generation of anti-idiotype immune responses following vaccination with idiotype-protein pulsed dendritic cells in myeloma. Br J Haematol. 1999;107:648-655.
6. Liso A, Stockerl-Goldstein KE, Auffermann-Gretzinger S, et al. Idiotype vaccination using dendritic cells after autologous peripheral blood progenitor cell transplantation for multiple myeloma. Biol Blood Marrow Transplant. 2000;6:621-627.
7. Lim SH, Bailey-Wood R. Idiotypic protein-pulsed dendritic cell vaccination in multiple myeloma. Int J Cancer. 1999;83:215-222.
8. Reichardt VL, Okada CY, Liso A, et al. Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma: a feasibility study. Blood. 1999;93:2411-2419.
9. Titzer S, Christensen O, Manzke O, et al. Vaccination of multiple myeloma patients with idiotype-pulsed dendritic cells: immunological and clinical aspects. Br J Haematol. 2000;108:805-816.
10. Wen YJ, Ling M, Bailey-Wood R, et al. Idiotypic protein-pulsed adherent peripheral blood mononuclear cell-derived dendritic cells prime immune system in multiple myeloma. Clin Cancer Res. 1998;4:957-962.
11. Yi Q, Desikan R, Barlogie B, et al. Optimizing dendritic cell-based immunotherapy in multiple myeloma. Br J Haematol. 2002;117:297-305.
12. Nestle FO, Banchereau J, Hart D. Dendritic cells: on the move from bench to bedside. Nat Med. 2001;7:761-765.
13. Lopez JA, Hart DN. Current issues in dendritic cell cancer immunotherapy. Curr Opin Mol Ther. 2002;4:54-63.
14. Egner W, Andreesen R, Hart DNJ. Allostimulatory cells in fresh human blood: heterogeneity in antigen-presenting cell populations. Transplantation. 1993;56:945-950.
15. MacDonald KPA, Munster D, Clark GC, et al. Characterization of human blood dendritic cell subsets. Blood. 2002;100:4512-4520.
16. Ratta M, Fagnoni F, Curti A, et al. Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6. Blood. 2002;100: 230-237.
17. Vuckovic S, Gardiner D, Field K, et al. Monitoring dendritic cells in clinical practice using a new whole blood single-platform TruCOUNT assay. J Immunol Methods. 2004;284:73-87.
18. Brown RD, Pope B, Murray A, et al. Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD40LT stimulation because of inhibition by transforming growth factor-beta(1) and interleukin-10. Blood. 2001;98:2992-2998.
19. Brown R, Murray A, Pope B, et al. Either interleukin-12 or interferon-gamma can correct the dendritic cell defect induced by transforming growth factor beta in patients with myeloma. Br J Haematol. 2004;125: 743-748.
20. Ratta M, Curti A, Fogli M, et al. Efficient presentation of tumor idiotype to autologous T cells by CD83(+) dendritic cells derived from highly purified circulating CD14(+) monocytes in multiple myeloma patients. Exp Hematol. 2000;28:931-940.
21. Pfeiffer S, Gooding RP, Apperley JF, et al. Dendritic cells generated from the blood of patients with multiple myeloma are phenotypically and functionally identical to those similarly produced from healthy donors. Br J Haematol. 1997;98:973-982.
22. Raje N, Gong J, Chauhan D, et al. Bone marrow and peripheral blood dendritic cells from patients with multiple myeloma are phenotypically and functionally normal despite the detection of Kaposi's sarcoma herpesvirus gene sequences. Blood. 1999;93:1487-1495.
23. Luft T, Jefford M, Luetjens P, et al. Functionally distinct dendritic cell (DC) populations induced by physiologic stimuli: prostaglandin E(2) regulates the migratory capacity of specific DC subsets. Blood. 2002;100:1362-1372.
24. De Vries IJ, Krooshoop DJ, Scharenborg NM, et al. Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state. Cancer Res. 2003;63:12-17.
25. Thomas R, Chambers M, Boytar R, et al. Immature human monocyte-derived dendritic cells migrate rapidly to draining lymph nodes after intradermal injection for melanoma immunotherapy. Melanoma Res. 1999;9:474-481.
26. Palucka KA, Taquet N, Sanchez-Chapuis F, et al. Dendritic cells as the terminal stage of monocyte differentiation. J Immunol. 1998;160:4587-4595.
27. Thurnher M, Zelle-Rieser C, Ramoner R, et al. The disabled dendritic cell. FASEB J. 2001;15:1054-1061.
28. Jefford M, Schnurr M, Toy T, et al. Functional comparison of DCs generated in vivo with Flt3 ligand or in vitro from blood monocytes: differential regulation of function by specific classes of physiologic stimuli. Blood. 2003;102:1753-1763.
29. Osugi Y, Vuckovic S, Hart DN. Myeloid blood CD11c(+) dendritic cells and monocyte-derived dendritic cells differ in their ability to stimulate T lymphocytes. Blood. 2002;100:2858-2866.
30. Reichardt VL, Okada CY, Liso A, et al. Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma: a feasibility study. Blood. 1999;93: 2411-2419.
31. Burch PA, Breen JK, Buckner JC, et al. Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer. Clin Cancer Res. 2000;6:2175-2182.
32. Small EJ, Fratesi P, Reese DM, et al. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol. 2000;18:3894-3903.
33. Lopez JA, Crosbie G, Kelly C, et al. Monitoring and isolation of blood dendritic cells from apheresis products in healthy individuals: a platform for cancer immunotherapy. J Immunol Methods. 2002;267: 199-212.
34. Lopez JA, Bioley G, Turtle CJ, et al. Single-step enrichment of blood dendritic cells by positive immunoselection. J Immunol Methods. 2003; 274:47-61.
35. Hock BD, Fearnley DB, Boyce A, et al. Human dendritic cells express a 95 kDa activation/differentiation antigen defined by CMRF-56. Tissue Antigens. 1999;53:320-334.
36. Lopez JA, Bioley G, Turtle CJ, et al. Single-step isolation of blood dendritic cells by positive immunoselection. J Immunol Methods. 2003; 274:47-61.
37. Vuckovic S, Kim M, Khalil D, et al. Granulocyte-colony stimulating factor increases CD123hi blood dendritic cells with altered CD62L and CCR7 expression. Blood. 2003;101:2314-2317.
38. Robinson SP, Patterson S, English N, et al. Human peripheral blood contains two distinct lineages of dendritic cells. Eur J Immunol. 1999;29: 2769-2778.
39. Ho CS, Munster D, Pyke CM, et al. Spontaneous generation and survival of blood dendritic cells in mononuclear cell culture without exogenous cytokines. Blood. 2002;99:2897-2904.
40. Maecker B, Anderson KS, von Bergwelt-Baildon MS, et al. Viral antigen-specific CD8+ T-cell responses are impaired in multiple myeloma. Br J Haematol. 2003;121:842-848.
41. Mozaffari F, Hansson L, Kiaii S, et al. Signalling molecules and cytokine production in T cells of multiple myeloma-increased abnormalities with advancing stage. Br J Haematol. 2004;124:315-324.
42. Vuckovic S, Gardiner D, Field K, et al. Monitoring dendritic cells in clinical practice using a new whole blood single-platform TruCOUNT assay. J Immunol Methods. 2004;284:73-87.
43. Mohty M, Olive D, Gaugler B. Plasmacytoid DCs and cancer: a new role for an enigmatic cell. Trends Immunol. 2004;25:397-398.
44. McIlroy D, Gregoire M. Optimizing dendritic cell-based anticancer immunotherapy: maturation state does have clinical impact. Cancer Immunol Immunother. 2003;52:583-591.
45. de Vries IJ, Lesterhuis WJ, Scharenborg NM, et al. Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients. Clin Cancer Res. 2003;9:5091-5100.
46. Spisek R, Bougras G, Ebstein F, et al. Transient exposure of dendritic cells to maturation stimuli is sufficient to induce complete phenotypic maturation while preserving their capacity to respond to subsequent restimulation. Cancer Immunol Immunother. 2003;52:445-454.
47. Kadowaki N, Ho S, Antonenko S, et al. Subsets of human dendritic cell precursors express different Toll-like receptors and respond to different microbial antigens. J Exp Med. 2001;194:863-869.
48. Jarrossay D, Napolitani G, Colonna M, et al. Specialization and complementarity in microbial molecule recognition by human myeloid and plasmacytoid dendritic cells. Eur J Immunol. 2001;31:3388-3393.
49. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol. 2003;3:133-146.
50. Jonuleit H, Kuhn U, Muller G, et al. Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur J Immunol. 1997;27: 3135-3142.
51. Langenkamp A, Messi M, Lanzavecchia A, et al. Kinetics of dendritic cell activation: impact on priming of TH1, TH2 and nonpolarized T cells. Nat Immunol. 2000;1:311-316.
52. Dhodapkar MV, Krasovsky J, Olson K. T cells from the tumor microenvironment of patients with progressive myeloma can generate strong, tumor-specific cytolytic responses to autologous, tumor-loaded dendritic cells. Proc Natl Acad Sci USA. 2002;99:13009-13013.